Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Perjeta
Pharma
BMS' Opdivo hits more approvable goal in early NSCLC
Opdivo's latest event-free survival win in neoadjuvant NSCLC adds to the drug's previous pathologic complete response success in the same trial.
Angus Liu
Nov 8, 2021 10:35am
AZ, Daiichi start Enhertu head-to-head trial in 1L breast cancer
Jun 14, 2021 10:35am
Roche pharma drops on biosimilar attack—again
Apr 21, 2021 11:25am
Roche CFO names innovation as Roche's defense against biosims
Jan 11, 2021 12:58pm
Roche wards off Herceptin copycats with Perjeta combo product
Jun 30, 2020 11:44am
SABCS: Roche's Perjeta builds case as HER2-positive add-on
Dec 11, 2019 8:00am
